Mounjaro vs. Wegovy (2026 UK Clinical Guide): Which Weight Loss Injection Is Better?

Search interest around Mounjaro vs. Wegovy in the UK has skyrocketed into the most queried comparison topic across online healthcare hubs. With the publication of direct head-to-head clinical trial data (such as SURMOUNT-5) and new dosage guidelines, patients exploring medical weight loss frequently ask: Which weekly injection delivers greater results, and how do they compare in price, mechanism, and side effects?

Whether you are deciding between treatments or seeking personalized prescribing advice, complete a private consultation via the WellAssist Pharmacy Hub or explore our core treatment hubs:

• Weight Management Solutions
• Situational Anxiety Treatments
• Propranolol Services

The Science in 60 Seconds

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both weekly subcutaneous weight loss injections approved in the UK. The primary difference lies in their mechanism: Wegovy acts solely on the GLP-1 receptor, whereas Mounjaro is a dual GIP / GLP-1 receptor agonist. In direct head-to-head clinical trials (SURMOUNT-5), patients taking Mounjaro achieved an average body weight loss of 20.2% over 72 weeks compared to 13.7% with Wegovy (2.4mg). However, Wegovy remains a trusted, established choice with proven cardiovascular risk reduction benefits.

Mechanism Breakdown: Single vs. Dual Hormone Agonism

                   ┌─────────────────────────────────────────┐
                   │    Injectable Weight Loss Therapies     │
                   └────────────────────┬────────────────────┘
                                        │
             ┌──────────────────────────┴──────────────────────────┐
             ▼ WEGOVY (SEMAGLUTIDE)                                 ▼ MOUNJARO (TIRZEPATIDE)
┌─────────────────────────┐                           ┌─────────────────────────┐
│ Single-Agonist Pathway  │                           │ Dual-Agonist Pathway    │
│ Mimics GLP-1 Hormone    │                           │ Mimics GLP-1 + GIP      │
└────────────┬────────────┘                           └────────────┬────────────┘
             │                                                     │
             ▼                                                     ▼
┌─────────────────────────┐                           ┌─────────────────────────┐
│ Delays Gastric Emptying │                           │ Enhanced Insulin & Fat  │
│ & Suppresses Appetite   │                           │ Metabolism + Appetite   │
└────────────┬────────────┘                           └────────────┬────────────┘
             │                                                     │
             ▼                                                     ▼
┌─────────────────────────┐                           ┌─────────────────────────┐
│ Avg 13.7% - 15% Weight  │                           │ Avg 20.2% - 22.5% Weight│
│ Reduction Over 68-72 Wks│                           │ Reduction Over 72 Wks   │
└─────────────────────────┘                           └─────────────────────────┘

1. Wegovy (Semaglutide)

Wegovy mimics the naturally occurring GLP-1 (glucagon-like peptide-1) hormone. It acts on the satiety centers in the brain to reduce hunger and delays stomach emptying so you feel full longer on smaller portions.

2. Mounjaro (Tirzepatide)

Mounjaro mimics two separate gut hormones: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism enhances fat oxidation and metabolic control while providing strong appetite suppression.

Head-to-Head Comparison: Mounjaro vs. Wegovy

Feature	Mounjaro (Tirzepatide)	Wegovy (Semaglutide)	Internal Link / Relevant Guide
Active Ingredient	Tirzepatide	Semaglutide	Weight Management Solutions
Mechanism	Dual Agonist (GIP + GLP-1)	Single Agonist (GLP-1)	Vaxia Pharma & Retatrutide Guide
Average Clinical Weight Loss	20.2% – 22.5%	13.7% – 15%	Oral GLP-1 Pills vs. Injections
Dosing Schedule	Weekly Injection (2.5mg – 15mg)	Weekly Injection (0.25mg – 2.4mg/7.2mg)	WellAssist Pharmacy Hub
Cardiovascular Evidence	SURMOUNT-MMO Trial Ongoing	Proven SELECT Trial Benefits	Combining GLP-1 & Anxiety Care
Stress & Cortisol Balance	Pairs with physical stress care	Pairs with physical stress care	Cortisol & Stress Weight Gain Guide

3 Practical Guidelines When Choosing Your Treatment

1. Evaluate Tolerability During Titration: Both treatments step up in dosage strength every 4 weeks. Gastrointestinal effects (nausea, mild reflux) are common during initial escalation; adhering to low-fat, smaller meals minimizes discomfort.
2. Address Psychological Stress & Physical Anxiety: High workplace stress raises cortisol levels, which can slow down weight loss progress. Managing physical anxiety through Propranolol Services or Situational Anxiety Treatments ensures a stable holistic foundation.
3. Commit to Long-Term Lifestyle Adjustments: Incretin therapies provide maximum benefit when integrated with progressive resistance exercise and balanced dietary protein intake to preserve lean muscle tissue.